Company intelligence / Profile preview

Bitrobius Genetics

Macclesfield / Alderley Park / Cheshire, England, United Kingdombitrobius.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

Bitrobius Genetics has developed the Gentrafix™ technology, a novel plasmid DNA system designed to deliver and replicate therapeutic genes across affected cells. The approach aims to overcome limitations of viral vectors by enabling delivery of large genes and widespread distribution within tissues. No clinical results have been published as of May 2025.

Therapeutic areas: Rare Diseases
Modalities: Plasmid DNA-based gene therapy (Gentrafix™ platform)
Industry: Biotech

Drug pipeline

1 asset

Gentrafix

Pre-clinical

Indications: Genetic diseases

Beyond the preview

Go deeper on Bitrobius Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bitrobius Genetics.

Explore the full profile